The successful management of SJS/TEN secondary to enfortumab vedotin therapy
A 47-year-old female with poorly differentiated carcinoma of urothelial origin on pembrolizumab, presented to the hospital with fever, dysuria, pruritus, diffuse erythema, and skin desquamation 11 days after starting immunotherapy with enfortumab vedotin (EV). The desquamation covered about 25% of h...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621922000266 |